IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies

Abstract excerpt

Mutations in isocitrate dehydrogenase (IDH) genes are among the most frequently encountered molecular alterations in cholangiocarcinoma (CCA). These neomorphic point mutations endow mutant IDH (mIDH) with the ability to generate an R-enantiomer of 2-hydroxyglutarate (R2HG), a metabolite that drives malignant transformation through aberrant epigenetic signaling. As a result, pharmacologic inhibition of mIDH has...

Topics

Join the communities discussing this publication.

• Cholangiocarcinoma and Gallbladder Cancer Studies
• Pancreatic and Hepatic Oncology Research
• Peptidase Inhibition and Analysis